PLK inhibitors identified by high content phenotypic screening promote maturation of human iPSC-derived cardiomyocytes

We performed RNA-Seq analysis of human pluripotent stem cells derived cardiomyocytes (hPSC-CMs) which were treated with Centrinone or Volasertib for 14 days to investigate the moleclular mechanism of inhibiting L-type calcium channel (LTCC) to promote cardiomyocyte proliferation. Overall design: RNA-Seq analysis of NM treated NRVCs and hPSC-CMs for 12 hours, 3 replicates per group.